Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $4,487,359 — Abstract - Core 3 The current SARS-CoV-2 pandemic is the third major pathogenic outbreak caused by a betaCoV in the last two decades. Development of panbetacoronavirus (panbetaCoV) vaccines for group 2b and group 2c beta CoVs is a major priority of this P01. In addition, this P01 will evaluate alpha…
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $1,904,952 — Abstract - Project 1 Zoonotic coronaviruses (CoV) are responsible for three major epidemics/pandemics in the 21st century, including Severe Acute Respiratory Coronavirus (SARS-CoV) in 2003 and Middle East Respiratory coronavirus (MERS- CoV) in 2012. In Dec 2019, a third novel coronavirus (CoV) desig…
Afamefuna Okoye · OREGON HEALTH & SCIENCE UNIVERSITY · 2021 · $844,491 — PROJECT SUMMARY Although the advent of combination antiretroviral therapy (cART) has dramatically improved the prognosis of people living with human immunodeficiency virus (HIV), cART alone cannot eradicate the infection and, therefore, daily treatment must be maintained for life to prevent relapse …
Amit Kapoor · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · 2021 · $642,072 — Abstract Although direct acting antivirals can cure Hepatitis C virus (HCV) infection, a vaccine is necessary to stop new infections, and to prevent re-infections in the cured individuals. Studies in humans and chimpanzees suggest that both T cells and neutralizing antibodies (nAb) can play an impor…
Elias Sayour · UNIVERSITY OF FLORIDA · 2021 · $472,806 — Project Summary While activated T cells cross the blood-brain barrier (BBB), immunotherapy has yet to be harnessed for targeted therapy due to GBM’s heterogeneity and immunosuppressive microenvironment. Unleashing immunotherapy against GBM requires new technologies that activate the tumor microenvir…
Blaine McCarthy · STANFORD UNIVERSITY · 2021 · $65,610 — Cancer vaccines have the potential to provide potent and personalized therapeutics with long-lasting effects for treatment of the ~100 million people worldwide currently affected by this disease. While recent advances have led to the first FDA-approved cancer vaccines, treatments that are broadly ef…
Abha Sahni · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $237,000 — PROJECT SUMMARY Precise and dynamic alterations in gene expression are critical determinants of the regulation of host immunity to microbial pathogens. Pathogenic rickettsiae in the spotted fever group cause some of the most severe infectious diseases in humans, characterized by microvascular inflam…
Mariah A Hassert · SAINT LOUIS UNIVERSITY · 2021 · $15,229 — Zika virus (ZIKV) spread explosively throughout the Americas in 2015, leaving in its wake a devastating and ever-expanding list of sequela associated with infection. Since this epidemic, substantial effort has been put forth to understand the emergence of ZIKV in the Americas, the course of disease …
Scott G Hansen · OREGON HEALTH & SCIENCE UNIVERSITY · 2021 · $800,450 — Project Summary With 36 million people currently living with HIV worldwide, developing a prophylactic HIV vaccine that protects against sexual transmission remains a top global health priority. A pre-clinical HIV vaccine approach based on strain 68-1 of rhesus cytomegalovirus expressing SIV antigens…
DARRICK Albert CARTER · PAI LIFE SCIENCES, INC. · 2021 · $86,791 — PROJECT SUMMARY RNA vaccines are a growing area of interest in vaccinology. They are flexible in that the purification process should be similar from one vaccine to the other and that they can be rapidly made in response to emerging diseases. Use of these nucleic acid constructs as a vaccine platfor…
Yuan Shi · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 · $360,159 — Project Summary Influenza A virus causes disease in 5-20% of the population with over 200,000 hospitalizations annually in US. The antigen drift and shift of influenza virus pose a serious challenge for flu vaccination program. Although IFN response is known as the first important host defending mec…
Laura Lynn Newcomb · CALIFORNIA STATE UNIV SAN BERNARDINO · 2021 · $110,250 — Influenza virus remains an unmet health issue. Although the virus is controlled with annual vaccines, these exhibit variable efficacy, and slow vaccine production means vaccines are not available during an emerging pandemic. Antivirals can stunt an influenza pandemic, but antivirals become ineffecti…
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2021 · $610,421 — ABSTRACT Influenza virus is one of the most important human infectious diseases. The influenza mortality is estimated to be approximately 650,000 per year worldwide, in addition, occasional global pandemics can infect up to 20- 40% of the world's population. Licensed influenza virus vaccines require…
Gabriel D Victora · ROCKEFELLER UNIVERSITY · 2021 · $454,516 — PROJECT SUMMARY/ABSTRACT Germinal centers (GCs) are site of antibody somatic hypermutation (SHM) and affinity maturation, and are therefore essential for effective humoral immune responses to pathogens. Efficient affinity maturation in GCs requires that B cells cycle between two different cell state…
Fredrick Heath Damron · WEST VIRGINIA UNIVERSITY · 2021 · $826,282 — PROJECT SUMMARY Pertussis is a respiratory disease caused by the obligate human pathogen Bordetella pertussis. Two generations of pertussis vaccines have been developed and licensed: whole cell pertussis (DTP) and acellular pertussis (DTaP/Tdap). Pertussis was thought to be a disease of the past but…
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $3,522,123 — A key goal of HIV-1 vaccine development is to induce long-lasting broadly neutralizing antibodies (bnAbs) that can inhibit HIV-1 infection. Messenger (m) RNA has emerged as a promising new vaccine modality that can elicit potent immune responses, while avoiding the safety risks and anti-vector immun…
Asok Antony · RLR VA MEDICAL CENTER · 2021 — Despite the advent of effective anti-Human Papillomavirus (HPV) vaccines, there are no biological agents to reliably prevent ~80 million Americans from transmitting their infectious HPV viral particles to sexual partners. Earlier we determined that the post-translational homocysteinylation of an mR…
ANDREW W GRIMSON · CORNELL UNIVERSITY · 2021 · $400,180 — Project Summary /Abstract Neonates are highly susceptible to infection and respond poorly to vaccination for reasons that are not well understood. Based on our published data, we believe that neonates are particularly vulnerable to repeat infections because their naïve CD8+ T cells are intrinsically…
Koichi Araki · CINCINNATI CHILDRENS HOSP MED CTR · 2021 · $454,637 — CD8 T cells play an important role in controlling viral infections as well as intracellular bacterial and parasitic infections. It is now clear that CD8 T cells are also involved in immunity against tumors and there is considerable interest in cancer immunotherapy that stimulates CD8 T cell response…
Christine Marie Durand · JOHNS HOPKINS UNIVERSITY · 2021 · $6,941,821 — Solid organ transplant recipients experience high mortality from COVID-19 due to a combination of immunosuppression and comorbidities. Although SARS-CoV-2 vaccination has been highly effective in the general population, recent studies show that solid organ transplant recipients are less likely to de…